Effects of pharmacological reversal of hyperuricemia on features of the metabolic syndrome in patients with gouty arthritis
Hyperuricemia has been associated in epidemiological studies with the development of obesity, hypertension, insulin resistance and type 2 diabetes. Nevertheless, it remains unclear whether lowering of serum uric acid (UA) alters any of the features of the metabolic syndrome. In this prospective stud...
Gespeichert in:
| Veröffentlicht in: | Journal of investigative medicine 2018-10, Vol.66 (7), p.1031-1036 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1036 |
|---|---|
| container_issue | 7 |
| container_start_page | 1031 |
| container_title | Journal of investigative medicine |
| container_volume | 66 |
| creator | Marin, Mariana Maalouf, Naim M |
| description | Hyperuricemia has been associated in epidemiological studies with the development of obesity, hypertension, insulin resistance and type 2 diabetes. Nevertheless, it remains unclear whether lowering of serum uric acid (UA) alters any of the features of the metabolic syndrome. In this prospective study (ClinicalTrials.gov identifier: NCT01654276), 24 patients with gouty arthritis and hyperuricemia were treated for 6 months with the xanthine oxidase inhibitor febuxostat to lower serum UA to |
| doi_str_mv | 10.1136/jim-2018-000728 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2022995714</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sage_id>10.1136_jim-2018-000728</sage_id><sourcerecordid>2022995714</sourcerecordid><originalsourceid>FETCH-LOGICAL-b423t-c9eac73a767c7bafe6e0e1ac40c0e5e543ab70baaf39c29829dca6617bbfe4763</originalsourceid><addsrcrecordid>eNqFkcGL1TAQh4Mo7rp69iYBL7JYN0nbpDnKsqvCghc9h0ne5DWPtqlJqjz85-2zq4IgnmZgvvlm4EfIc87ecF7Lq0MYK8F4VzHGlOgekHOuWFd1QqqHa886XrVtp8_Ik5wPjAnZavGYnAkthVBte06-33iPrmQaPZ17SCO4OMR9cDDQhF8x5bVZZ_1xxrSk4HAMQONEPUJZEv5cLD3SEQvYOARH83HapTgiDROdoQScVv23UHq6j0s5UkilT6GE_JQ88jBkfHZfL8jn25tP1--ru4_vPly_vatsI-pSOY3gVA1KKqcseJTIkINrmGPYYtvUYBWzAL7WTuhO6J0DKbmy1mOjZH1BXm3eOcUvC-ZixpAdDgNMGJdsBBNC61bxZkVf_oUe4pKm9TsjOG95XXNxEl5tlEsx54TezCmMkI6GM3PKxay5mFMuZstl3Xhx713siLvf_K8gVuD1BmTY45-j__ZdbrgdD_89_gP-Laat</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2115133126</pqid></control><display><type>article</type><title>Effects of pharmacological reversal of hyperuricemia on features of the metabolic syndrome in patients with gouty arthritis</title><source>Access via SAGE</source><creator>Marin, Mariana ; Maalouf, Naim M</creator><creatorcontrib>Marin, Mariana ; Maalouf, Naim M</creatorcontrib><description>Hyperuricemia has been associated in epidemiological studies with the development of obesity, hypertension, insulin resistance and type 2 diabetes. Nevertheless, it remains unclear whether lowering of serum uric acid (UA) alters any of the features of the metabolic syndrome. In this prospective study (ClinicalTrials.gov identifier: NCT01654276), 24 patients with gouty arthritis and hyperuricemia were treated for 6 months with the xanthine oxidase inhibitor febuxostat to lower serum UA to <6 mg/dL. Measurements of 24 hours ambulatory blood pressure (ABP) and serum and urine markers of the metabolic syndrome were measured at baseline and at the end of 6 months of febuxostat. The study population consisted of 18 men and 6 women, 18 of which completed the baseline and 6 months visits. Serum UA decreased significantly from 8.7±1.5 mg/dL at baseline to 4.4±1.1 mg/dL at 6 months (P<0.0001). During that time frame, there was no significant change in body mass index, systolic or diastolic blood pressure measured by 24 hours ABP monitor, serum glucose, insulin or homeostatic model assessment for insulin resistance, serum total and high-density lipoprotein-cholesterol, serum triglycerides or urine pH (P>0.05 for all). There was no correlation between parameters of the metabolic syndrome and the decline in serum UA or serum UA achieved at study end. In conclusion, in patients with gouty arthritis, UA lowering with febuxostat below 6 mg/dL had no significant impact on features of the metabolic syndrome.</description><identifier>ISSN: 1081-5589</identifier><identifier>EISSN: 1708-8267</identifier><identifier>DOI: 10.1136/jim-2018-000728</identifier><identifier>PMID: 29622755</identifier><language>eng</language><publisher>Los Angeles, CA: SAGE Publications</publisher><subject>Arthritis ; Blood pressure ; Diabetes ; Drug dosages ; Fasting ; Heart failure ; Hypertension ; Insulin resistance ; Internal medicine ; Kidney diseases ; Metabolic syndrome ; Studies ; Systematic review ; Uric acid ; Urine</subject><ispartof>Journal of investigative medicine, 2018-10, Vol.66 (7), p.1031-1036</ispartof><rights>American Federation for Medical Research (unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.</rights><rights>2018 American Federation for Medical Research</rights><rights>2018 American Federation for Medical Research (unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-b423t-c9eac73a767c7bafe6e0e1ac40c0e5e543ab70baaf39c29829dca6617bbfe4763</citedby><cites>FETCH-LOGICAL-b423t-c9eac73a767c7bafe6e0e1ac40c0e5e543ab70baaf39c29829dca6617bbfe4763</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://journals.sagepub.com/doi/pdf/10.1136/jim-2018-000728$$EPDF$$P50$$Gsage$$H</linktopdf><linktohtml>$$Uhttps://journals.sagepub.com/doi/10.1136/jim-2018-000728$$EHTML$$P50$$Gsage$$H</linktohtml><link.rule.ids>314,780,784,21819,27924,27925,43621,43622</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29622755$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Marin, Mariana</creatorcontrib><creatorcontrib>Maalouf, Naim M</creatorcontrib><title>Effects of pharmacological reversal of hyperuricemia on features of the metabolic syndrome in patients with gouty arthritis</title><title>Journal of investigative medicine</title><addtitle>J Investig Med</addtitle><description>Hyperuricemia has been associated in epidemiological studies with the development of obesity, hypertension, insulin resistance and type 2 diabetes. Nevertheless, it remains unclear whether lowering of serum uric acid (UA) alters any of the features of the metabolic syndrome. In this prospective study (ClinicalTrials.gov identifier: NCT01654276), 24 patients with gouty arthritis and hyperuricemia were treated for 6 months with the xanthine oxidase inhibitor febuxostat to lower serum UA to <6 mg/dL. Measurements of 24 hours ambulatory blood pressure (ABP) and serum and urine markers of the metabolic syndrome were measured at baseline and at the end of 6 months of febuxostat. The study population consisted of 18 men and 6 women, 18 of which completed the baseline and 6 months visits. Serum UA decreased significantly from 8.7±1.5 mg/dL at baseline to 4.4±1.1 mg/dL at 6 months (P<0.0001). During that time frame, there was no significant change in body mass index, systolic or diastolic blood pressure measured by 24 hours ABP monitor, serum glucose, insulin or homeostatic model assessment for insulin resistance, serum total and high-density lipoprotein-cholesterol, serum triglycerides or urine pH (P>0.05 for all). There was no correlation between parameters of the metabolic syndrome and the decline in serum UA or serum UA achieved at study end. In conclusion, in patients with gouty arthritis, UA lowering with febuxostat below 6 mg/dL had no significant impact on features of the metabolic syndrome.</description><subject>Arthritis</subject><subject>Blood pressure</subject><subject>Diabetes</subject><subject>Drug dosages</subject><subject>Fasting</subject><subject>Heart failure</subject><subject>Hypertension</subject><subject>Insulin resistance</subject><subject>Internal medicine</subject><subject>Kidney diseases</subject><subject>Metabolic syndrome</subject><subject>Studies</subject><subject>Systematic review</subject><subject>Uric acid</subject><subject>Urine</subject><issn>1081-5589</issn><issn>1708-8267</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqFkcGL1TAQh4Mo7rp69iYBL7JYN0nbpDnKsqvCghc9h0ne5DWPtqlJqjz85-2zq4IgnmZgvvlm4EfIc87ecF7Lq0MYK8F4VzHGlOgekHOuWFd1QqqHa886XrVtp8_Ik5wPjAnZavGYnAkthVBte06-33iPrmQaPZ17SCO4OMR9cDDQhF8x5bVZZ_1xxrSk4HAMQONEPUJZEv5cLD3SEQvYOARH83HapTgiDROdoQScVv23UHq6j0s5UkilT6GE_JQ88jBkfHZfL8jn25tP1--ru4_vPly_vatsI-pSOY3gVA1KKqcseJTIkINrmGPYYtvUYBWzAL7WTuhO6J0DKbmy1mOjZH1BXm3eOcUvC-ZixpAdDgNMGJdsBBNC61bxZkVf_oUe4pKm9TsjOG95XXNxEl5tlEsx54TezCmMkI6GM3PKxay5mFMuZstl3Xhx713siLvf_K8gVuD1BmTY45-j__ZdbrgdD_89_gP-Laat</recordid><startdate>20181001</startdate><enddate>20181001</enddate><creator>Marin, Mariana</creator><creator>Maalouf, Naim M</creator><general>SAGE Publications</general><general>Sage Publications Ltd</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>0-V</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AM</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ALSLI</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>BGRYB</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>K7.</scope><scope>K9.</scope><scope>M0O</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>20181001</creationdate><title>Effects of pharmacological reversal of hyperuricemia on features of the metabolic syndrome in patients with gouty arthritis</title><author>Marin, Mariana ; Maalouf, Naim M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b423t-c9eac73a767c7bafe6e0e1ac40c0e5e543ab70baaf39c29829dca6617bbfe4763</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Arthritis</topic><topic>Blood pressure</topic><topic>Diabetes</topic><topic>Drug dosages</topic><topic>Fasting</topic><topic>Heart failure</topic><topic>Hypertension</topic><topic>Insulin resistance</topic><topic>Internal medicine</topic><topic>Kidney diseases</topic><topic>Metabolic syndrome</topic><topic>Studies</topic><topic>Systematic review</topic><topic>Uric acid</topic><topic>Urine</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Marin, Mariana</creatorcontrib><creatorcontrib>Maalouf, Naim M</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Social Sciences Premium Collection</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Criminal Justice Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>Social Science Premium Collection</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>Criminology Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest Criminal Justice (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Criminal Justice Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of investigative medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Marin, Mariana</au><au>Maalouf, Naim M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effects of pharmacological reversal of hyperuricemia on features of the metabolic syndrome in patients with gouty arthritis</atitle><jtitle>Journal of investigative medicine</jtitle><addtitle>J Investig Med</addtitle><date>2018-10-01</date><risdate>2018</risdate><volume>66</volume><issue>7</issue><spage>1031</spage><epage>1036</epage><pages>1031-1036</pages><issn>1081-5589</issn><eissn>1708-8267</eissn><abstract>Hyperuricemia has been associated in epidemiological studies with the development of obesity, hypertension, insulin resistance and type 2 diabetes. Nevertheless, it remains unclear whether lowering of serum uric acid (UA) alters any of the features of the metabolic syndrome. In this prospective study (ClinicalTrials.gov identifier: NCT01654276), 24 patients with gouty arthritis and hyperuricemia were treated for 6 months with the xanthine oxidase inhibitor febuxostat to lower serum UA to <6 mg/dL. Measurements of 24 hours ambulatory blood pressure (ABP) and serum and urine markers of the metabolic syndrome were measured at baseline and at the end of 6 months of febuxostat. The study population consisted of 18 men and 6 women, 18 of which completed the baseline and 6 months visits. Serum UA decreased significantly from 8.7±1.5 mg/dL at baseline to 4.4±1.1 mg/dL at 6 months (P<0.0001). During that time frame, there was no significant change in body mass index, systolic or diastolic blood pressure measured by 24 hours ABP monitor, serum glucose, insulin or homeostatic model assessment for insulin resistance, serum total and high-density lipoprotein-cholesterol, serum triglycerides or urine pH (P>0.05 for all). There was no correlation between parameters of the metabolic syndrome and the decline in serum UA or serum UA achieved at study end. In conclusion, in patients with gouty arthritis, UA lowering with febuxostat below 6 mg/dL had no significant impact on features of the metabolic syndrome.</abstract><cop>Los Angeles, CA</cop><pub>SAGE Publications</pub><pmid>29622755</pmid><doi>10.1136/jim-2018-000728</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1081-5589 |
| ispartof | Journal of investigative medicine, 2018-10, Vol.66 (7), p.1031-1036 |
| issn | 1081-5589 1708-8267 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2022995714 |
| source | Access via SAGE |
| subjects | Arthritis Blood pressure Diabetes Drug dosages Fasting Heart failure Hypertension Insulin resistance Internal medicine Kidney diseases Metabolic syndrome Studies Systematic review Uric acid Urine |
| title | Effects of pharmacological reversal of hyperuricemia on features of the metabolic syndrome in patients with gouty arthritis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-03T21%3A51%3A44IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effects%20of%20pharmacological%20reversal%20of%20hyperuricemia%20on%20features%20of%20the%20metabolic%20syndrome%20in%20patients%20with%20gouty%20arthritis&rft.jtitle=Journal%20of%20investigative%20medicine&rft.au=Marin,%20Mariana&rft.date=2018-10-01&rft.volume=66&rft.issue=7&rft.spage=1031&rft.epage=1036&rft.pages=1031-1036&rft.issn=1081-5589&rft.eissn=1708-8267&rft_id=info:doi/10.1136/jim-2018-000728&rft_dat=%3Cproquest_cross%3E2022995714%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2115133126&rft_id=info:pmid/29622755&rft_sage_id=10.1136_jim-2018-000728&rfr_iscdi=true |